Articles





Larimar Therapeutics

Larimar Therapeutics Advances Nomlabofusp Clinical Program with First Patient Dosed in Open Label Extension Study

BALA CYNWYD, PA — Clinical-stage biotechnology company Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the dosing of the first patient in an open label extension (OLE) study for its novel …

Larimar Therapeutics Advances Nomlabofusp Clinical Program with First Patient Dosed in Open Label Extension Study Read More